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Sarcopenia in Older Adults
Eli Carmeli
Abstract
Sarcopenia has become of great interest and focus of many studies since this 
phenomenon affects many people. Moreover, sarcopenia is associated with two 
more pandemic phenomena: frailty and obesity. These health-related conditions are 
increasing in western countries in general and in the older population in particular. 
Each of such health conditions relates to functional decline, yet the combination 
of two or three of them in one person severely affects quality of life and longevity. 
Aged individuals who are less physically active are more likely to develop sarcopenic 
obesity, and those who are obese with muscle weakness and inactive are disposed 
to become frail individuals. Hence, frailty and obesity overlap profoundly with the 
physical manifestations of sarcopenia of aging. These “unhappy” triads encom-
passes a wider range of geriatric decline that also includes cognitive, psychology and 
social deterioration associated with adverse outcomes. Nevertheless, this chapter 
focuses only on sarcopenia and will review the pathophysiological background of 
age-related decline in muscle mass and strength.
Keywords: sarcopenia, elderly, strength, muscle mass, physical performance, 
radicals, cytokines
1. Introduction
1.1 The “unhappy triad”
The end of the last century and the beginning of the first two decades of the 
present century were characterized by the rise of three medical or health pandemic 
phenomena, each of which has a serious impact on public health and especially 
among older people. These three conditions are frailty, sarcopenia, and obesity. 
When sarcopenia or frailty is also accompanied by obesity, a sarcopenic/frail-obese 
phenotype is established [1]. Moreover, the presence of these “unhappy triads” of 
health conditions, in one person, poses a significant threat to one’s quality of life 
and longevity. The prevalence of each of such conditions (i.e., frailty, sarcopenia, 
and obesity) is widely estimated within different countries; however, with no one 
single best outcome measure for these diagnoses, there is highly wide range of 
manifestation and diagnoses in each of these health phenomena [2].
A “cycle of sarcopenia” may be created in which in the presence of one or two 
factors such as frailty and or obesity, sarcopenia status is likely to continue to dete-
riorate unless there is outside intervention. It is extremely difficult to overcome this 
“unhappy triad” when the affected people do not have the resources necessary to 
get out of muscle weakness and fatigue, such as lower cardiac function (myocardial 
infraction, angina, chronic heart failure, metabolic state (hypertension, diabetes, 
and obesity) and arthritis.
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Longevity steadily increased over the past several decades. Life expectancy in 
65 year Western country subjects is ~20 years, and the proportion of people over 
age 60 is increasing faster than any other groups (2). Obesity is also worldwide 
growing [3] and is also accompanied by significant alterations in body composition, 
with a decline in lean body mass and muscle strength and with an increase in fat 
mass. This phenomenon known as sarcopenic obesity [4].
The concept of frailty syndrome is basically a geriatric syndrome, which is 
recently becoming one of the dominant concepts in advanced age. Frailty is a dynamic 
condition with the presence of several components. There are two major operational 
definitions for frailty. The most widely used concept is the Fried physical frailty phe-
notype, which defines frailty based on three or more of the following five symptoms: 
unintentional weight loss, slowness, weakness, exhaustion, and low physical activity 
[5]. Yet, functional decline due to sarcopenia is in the core of frailty syndrome [6].
This chapter focuses on sarcopenia. Aged skeletal muscles can be induced to die 
through different mechanisms mainly via two systems, apoptosis or autophagy; 
both systems can be activated through different molecules such as free radicals, 
inflammatory molecules, hormones, and others [7].
2. Sarcopenia
There are currently over 10,000 articles published in referee journals dealing 
with the phenomenon of Sarcopenia, which was first proposed by Irwin Harold 
Rosenberg in 1989 at the annual conference of the American Society for Clinical 
Nutrition. Sarcopenia is age-related myopenia (decrease of muscle mass) and dyna-
penia (decrease in muscle strength) [8]. More specifically, sarcopenia is a health 
problem of old people characterized by a slow, progressive skeletal muscle disorder 
involving the accelerated loss of muscle mass and strength followed by the func-
tional decline that is associated with falls, obesity, frailty, frequent hospitalization, 
and mortality [9]. Sarcopenia has become of great interest and focus of many studies 
and since this phenomenon affects many people, the number of older population 
with sarcopenia is expected to increase all over the world, and it is becoming one of 
the important and interests, and causes a great deal of financial burden, a private 
and a public concern, from the individual level to the state and various institutions 
that deal with welfare and health [10]. It predisposed by genetic profile and lifestyle 
factors occurring across the life course [11]. The expression of Let-7b and Let-7e 
microRNA precursors (regulating muscle apoptosis) is significantly higher in older 
versus younger subjects. Ingenuity pathway analysis identified that the Let-7 family 
predicted gene targets were related to pathways and biological functions associated 
with macrophages activity.
Therefore, a great deal of knowledge about the nature of the phenomenon 
was accumulated, from a biological and clinical point of view, different means to 
diagnose it, and with particular ways to treat it such as nutritional interventions and 
drugs to augment the beneficial effects of resistance exercise.
2.1 Definition of sarcopenia
Sarcopenia (Greek “sarx” or flesh + “penia” or loss) is a geriatric syndrome 
which is described as a progressive decline in skeletal muscle mass and muscle 
strength from approximately the fifth decade of life.
The European Working Group on Sarcopenia in Older People (EWGSOP) 
defined sarcopenia in 2010 as a quote: “a syndrome characterized by progressive 
and generalized loss of skeletal muscle mass and strength with the risk of adverse 
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outcome such as physical disability, poor quality of life, and death” [12]. The 
EWGSOP proposed that age-related muscle weakness is considered as “primary 
sarcopenia” when no other reason is evident except aging itself. EWGSOP also sug-
gests a concept of three phases of sarcopenia: pre-sarcopenia (there is low muscle 
mass without low muscle strength or decline in physical performance); sarcopenia 
(low muscle mass, accompanying either low muscle strength or low physical perfor-
mance); and severe sarcopenia (when all three criteria are detected).
Another consensus definition of primary sarcopenia done by the International 
Working Group for Sarcopenia (IWGS) as “an individual presents functional and 
mobility decline, history of recurrent falls, recent unwanted body weight loss, 
recent-hospitalization, and chronic metabolic diseases (e.g., diabetes, hypothyroid) 
malnutrition, low protein intake, and cancer” [13].
2.2 Prevalence and epidemiology of sarcopenia
It is well known and extensively documented that as an older person reaches his 
sixth decade of life, there is a progressive decline in muscle mass (~1% per year) 
and strength (~2.5–3% per year) [14]. Sarcopenia is more prevalent in men than in 
women. It is more prevalent in large muscle groups such as tight, more in untrained 
individuals and more in people with poor health background [15]. There is a strong 
association between, muscle strength, age, gender, and disability. In general, there 
is a decrease in muscle mass at an annual rate of 1.5% after about 50 years old, 
reaching to 3% per year in their eight decade [16].
Public health planners, physicians and researchers are needed to come up with 
the consensus of criteria for estimating the prevalence of sarcopenia. Moreover, at 
present time, there are lacking data for developing any consensus on what consti-
tutes poor muscle mass, and what is the optimal, valid, and reliable tool to measure 
and to diagnose sarcopenia.
The prevalence of sarcopenia needs to be investigated in multiethnic population, 
and to explore association with obesity, socioeconomic status, mental and cognitive 
function, morbidity, quality of life, and life style. Previous studies have been dem-
onstrated associations between muscle mass and function, whereas other studies 
have established associations between the following:
a. sarcopenia and physical activity [17],
b. muscle mass and BMI [18];
c. muscle performance and certain minerals [19];
d. muscle mass and strength and depressive symptoms and [20];
e. sarcopenia and cognitive impairment [21];
f. muscle strength and falls [22];
g. muscle mass and osteoporosis [23], thus those with sarcopenia possessed ap-
proximately 13 times higher risk of having osteoporosis [24], and there is a 
significant association between osteoporosis and deterioration of the skeletal 
microarchitecture [25]. The prevalence of osteosarcopenia increases with aged 
men and women [26]; and
h. sarcopenia and meat intake in male and milk intake in female [27].
Muscular Atrophy
4
3.  Biological mechanisms of sarcopenia: from molecular  
to histological level
There are several molecular mechanisms that may be involved, in some degree, 
in the commencement and development of sarcopenia. Although the molecular and 
cellular mechanisms underlying sarcopenia still remain to be clarified, certain com-
mon biological mechanisms have been suggested to be involved in sarcopenia. This 
section will include, in brief, the most common mechanisms related to sarcopenia: 
oxidative stress [reactive oxygen and nitrogen species (ROS and RNS)]; a-without 
clinical symptoms of muscle fiber inflammation (due to presence of myokines/cyto-
kines like TNF-α and IL-6); hormonal regulation impairment (such as testosterone, 
growth hormone, IGF-1, glutathione 4, insulin resistance, and vitamin D); vitamin 
E deficiency; proteolysis pathway [the lack of responsiveness of the ubiquitin-
proteasome system and alterations in the regulation of autophagy and apoptotic 
pathway (Bcl2 signaling and NF-Kb)]; and finally, the role of adult stem (satellite) 
cells. Identifying these mechanisms and their underlying origins is expected to 
facilitate strategy of intervention programs [28].
From a physiology and histology point of view, the skeletal muscle comprises 
several types of fibers. The most prominent types are type I and type II fibers. 
Type II fast twitch muscle fibers characterized by high glycolytic potential, lower 
oxidative capacity, and faster response, are aimed at muscle strength and short-
duration anaerobic activities, whereas type I slow twitch muscle fibers are known 
as fatigue-resistant due to their characteristics such as large density of capillary bed 
and myoglobin and being abundant with mitochondria, to better supply oxygen 
and nutrients to the muscle, thus to improve muscular endurance and aerobic 
activities [29].
Sarcopenia is characterized by more hypotrophy and less fiber activation of 
the lower extremity muscles than upper limbs. Moreover, the lower limb muscles 
of old people are smaller and have significantly more fats and connective tissues 
than lower limb muscles in young individuals. Sarcopenia is characterized by a 
reduction in both the number and size of muscle fibers, mainly of type II, and is to 
some extent caused by a slowly progressive myogenic process, which is stem cells 
dependent. Therefore, these changes affect not only in energy production, poor 
muscle repair, and deprived fiber regeneration, but also practically in decline in 
physical performance and in functional capacity such as walking (stairs), running, 
and early onset of fatigue which all associate with poor quality of life and more 
dependency [30].
Of course there is a connection and interdependence between the various 
factors. Sometimes one of them is a cause or effect, and sometimes it is a result of 
or outcome from. Some of the mechanisms have a positive correlation and oth-
ers have a negative correlation. In general, skeletal muscle can “die” in different 
molecular pathways. Sarcopenia, as a normal physiological process, is associated 
with a significant rise in the levels of inflammatory molecules both in blood serum 
and intra- and extracellular. The aging process induced oxidative stress (OS) and 
degradation of damaged mitochondria promotes the accumulation of lipofuscin, 
which is one histological marker of fiber oxidative damage. The accumulation of 
lipofuscin, is recognized as the hallmark pigment of aging muscle. Lipofuscin is an 
intralysosomal, composed of cross-linked protein residues and lipid per oxidized 
molecules. This intracellular waste material interferes with muscle metabolism and 
muscle contraction [31].
Oxidative stress resulted due to imbalance between the production of reactive 
oxygen/nitrogen species and antioxidants/nitrogen defense molecules. Consequently 
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and practically, a chain response of inflammatory molecules appears within the 
fibers with the release of myokines such as tumor necrosis factor-α (TNF-α), inter-
leukin-6 (IL-6), and interleukin-1 (IL-1) that lead to a predisposition to age-related 
sarcopenia afterward through the activation of the ubiquitin-protease system and 
the activation of myofiber signaling pathway that leads to muscle apoptosis. It is also 
suggested that cytokines also contributes to anabolic resistance through provoking 
the anabolic effect mediated by insulin growth factor-1 (IGF-1), involving in growth 
hormone resistance which limits IGF-I availability. Some other potential factors and 
mechanisms are suggested leading to sarcopenia such as TGF-β-activated kinase 
(TAK)-1; C-reactive protein; a significant reduction of dihydropyridine (DHP)-
sensitive Ca2+ (the decrease of Ca2+ available for mechanical responses in aged 
skeletal muscle is due to DHP receptor (DHPR)-ryanodine receptor (RyR) uncou-
pling); and the stress of sarcoplasmic reticulum due to accumulation of unfolded or 
misfolded proteins like heat shock proteins.
3.1 Oxidative stress and sarcopenia
Sarcopenia is a multifactorial event, thus redox signaling and oxidative stress 
have a key role play, due to an increase in reactive oxygen and nitrogen species 
(ROS/RNS) levels, a decrease in enzymatic antioxidant protection and followed 
by myofiber “quiet” inflammation (i.e., the presence of myokines). Therefore, the 
oxidative stress is more extensively described in the below section of this chapter.
3.1.1  Endogenous sources of reactive oxygen species, reactive nitrogen species,  
and antioxidant systems
Reactive oxygen species (ROS) are mainly and normally produced by the mito-
chondria, and a normal ROS level is indispensable for myofiber functions.
The mitochondrial electron transport chain transfer of a single electron to 
molecular oxygen gives rise to a monovalent reduction of oxygen, which leads to 
the formation of superoxide ions (O2.−). It is the first step in the chain of events 
to create more free radicals such as hydrogen peroxide (H2O2), hydroxyl radical 
(OH.), and hydroxyl ion (OH−) [32]. Another source of ROS in skeletal muscle is 
a large NOX family enzymes (NOX1, NOX2, and NOX4) located in the sarcoplas-
mic reticulum, transverse tubule, and also in the sarcoplasma membrane [33]. 
These enzymes have the capacity to transport electrons across the sarcoplasma 
membrane and generate superoxide and other downstream reactive oxygen 
species (ROS). Since these enzymes play an important role in excitation con-
traction coupling, hyperexpression or overproduction of NOXs inhibits muscle 
contractions. Another mechanism that can explain the crosstalk between NOXs 
and ROS production is the rise of intracellular Ca2+ levels by NOX-derived ROS, 
which, increasing mitochondrial Ca2+ load, induces the ROS production by these 
organelles.
Reactive nitrogen species (RNS) derived from nitric oxide (•NO) and superoxide 
ions is produced via the enzymatic activity of inducible nitric oxide synthase 2 
(NOS2) and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) 
[34]. NOS2 is also expressed after induction of cytokines [26]. In skeletal muscle, 
there are three different isoforms of this isoenzyme: endothelial NOS (eNOS), neu-
ronal NOS (nNOS), and inducible isoform (iNOS). RNS arise from several sources 
and the levels increase with contractile activity. Nitric oxide (NO) is formed from 
L-arginine in a reaction catalyzed by the nitric oxide synthase (NOS) enzyme, and it 
is an important cell signaling molecule [35].
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The intrinsic and extrinsic antioxidant systems inhibit oxidation [36, 37]. The 
intrinsic system includes enzymes such as superoxide dismutase, catalase, peroxi-
dase, and glutathione. Manganese superoxide dismutase (MnSOD) is synthesized by 
a mitochondrion that catalyzes the breakdown of the superoxide anion into oxygen 
and hydrogen peroxide. Catalase catalyzes the conversion of hydrogen peroxide to 
water and oxygen, peroxidase catalyzes the reduction of hydrogen peroxide, and 
glutathione is a very efficient scavenger of hydrogen peroxide, while glutathione 
peroxidase 4 is most active with lipid hydroperoxides. The extrinsic system includes 
dietary supplements such as Ubiquinone-10, coenzyme Q10, creatine, and others, 
and the combination with physical exercise is even better for muscle atrophy preven-
tion and/or treatment of sarcopenia [38].
The levels of ROS and RNS inside the fibers are firmly controlled by the bal-
ance between the rate of endogenous synthesis by ROS/RNS generating systems 
and the rate of removal through the nonenzymatic and enzymatic antioxidant 
systems [39]. In aged muscles, there is an excessive ROS/RNS production or 
diminishing of antioxidant production which interrupts the myofiber metabolism 
and physiological function, both in resting and in force production [40]. There 
is plenty of evidence that sarcopenia is caused by an increase of endogenous ROS 
and/or RNS formation, on the one hand, and decrease in quantity, quality, and 
antioxidant system efficiency, on the other hand [41, 42]. Sarcopenia is also char-
acterized by mitochondrial dysfunction; mitochondrial morphological changes, 
lacking fusion and fission; less mitochondria mobility, leading to the accumula-
tion of damaged mitochondria that induces a catabolic process; muscle loss; and 
fiber inflammation [43, 44].
In conclusion, age-related ROS and RNS overproduction not only generates 
damage of muscle but also plays a role in regulating intracellular signal transduction 
pathways that are directly or indirectly involved in skeletal muscle inflammation 
and apoptosis.
3.1.2 The role of cytokines in sarcopenia
Sarcopenia is definitely associated with inflammatory cytokines/myokines, 
which prompt a serious negative consequence as a loss of muscle mass and strength 
with concomitant increase in fat mass, eventually stimulating protein catabolism 
and muscle degeneration. As such, an excepted catabolic inflammatory process 
is often observed in older adults, and it can enhance and deteriorate the status of 
sarcopenia [45].
Skeletal muscle tissue is an vital source of inflammatory molecules, known as 
“myokines” (e.g., IL-6, IL-1b, TNFα, and IL-1ra) which are overexpressed in aged 
skeletal muscles, related to the slow, non symptomatic, slowly progressed, inflam-
mation process demonstrated in elderly individuals. Myokines are secreted in 
response to muscle contraction or strength training [46]; however, their activation 
as inflammatory signal pathways happen due to aging, which reveals their critical 
impact on sarcopenia [47]. Several inflammatory myokines, especially interleukin-1 
6, and 10 (IL-1, Il-6, IL-10), tumor necrosis factor-alpha (TNF-α), and myostatin 
play crucial roles in the modulation of inflammatory signaling pathway during the 
aging-related loss of skeletal muscle [48, 49].
3.1.2.1 Interleukin
The relationship between sarcopenia and the inflammatory cytokines interleu-
kin-1 and 6 (IL-1, IL-6), and the anti-inflammatory cytokine interleukin-10 (IL-10) 
in an elderly population is well reported [50, 51]. IL-6 within the muscle fibers 
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promotes glucose uptake and fat oxidation via the phosphoinositide 3-kinase (PI3K) 
and AMP-activated protein kinase (AMPK) signaling pathways, respectively, and 
improves insulin sensitivity by blocking the proinflammatory signaling pathways 
in the muscle. High levels of IL-6 (>40 pg./ml) and IL-10 (>4 pg./ml) are associ-
ated with lower physical performance, muscle strength, and muscle mass [52]. 
Hospitalized geriatric patients with inflammation represented significantly weaker 
muscle function, shoulder extension strength, and a worse fatigue resistance [53]. 
Old people living in nursing homes and long-term-assisted living facilities present-
ing high IL-6 levels were associated with the higher prevalence of frailty [54]. The 
significant role of IL-6 levels on depressive symptoms in older women in the year 
after hip fracture may represent a sickness syndrome that is chronic in some indi-
viduals [55]. A recent study in community-dwelling older men suggested that the 
high levels of interleukin-1 (IL-1) is associated with a low grip strength [56]. The 
ratio of proinflammatory cytokine IL-6 to anti-inflammatory cytokine IL-10 (IL-6/
IL-10 ratio) >9.5 pg./ml has been used as a reliable marker for measuring inflamma-
tory status [57].
IL-10 is an anti-inflammatory myokine, mostly produced by macrophages, 
T-helper 2 cells (also known as CD4+ cells), B-lymphocytes, and monocytes. These 
cells either secrete antibodies or suppress and destroy any immune response. IL-10 
is responsible for destroying the proinflammatory response in various tissues, 
including skeletal muscle, by suppressing the activation of phagocytes such as 
macrophages and releasing and activating the inflammatory cytokines such as 
IL-6, TNFα, and IL-1β. Increased IL-10 was associated with poor physical perfor-
mance [58, 59].
In summary, inflammatory and proinflammatory interleukin cytokines have 
both been linked with a number of age-related outcomes, including sarcopenia, 
chronic morbidity, functional decline, and mortality [60].
3.1.2.2 Tumor necrosis factor-α (TNF-α)
The appearance of sarcopenia is accompanied by the increased levels of inflam-
mation factors such as TNF-α. TNF-α inhibits the synthesis of muscle proteins, 
accelerates protein decomposition, and upregulates the expression of muscle 
growth inhibitory factor myostatin and muscle atrophy proteins, F-box-1 Atrogin-1, 
etc., so as to accelerate protein catabolism and promote skeletal muscle consump-
tion. TNF-α and its soluble receptors showed the most consistent associations with 
decline in muscle mass and strength [61]. TNF-α is also reported to suppress the 
Akt/mTOR pathway [62], promoting muscle catabolism, oxidative stress, and nitric 
acid production [63].
3.1.2.3 C-reactive protein (CRP)
Elevated levels of these proteins, reflecting the conditions of chronic inflamma-
tion, have been associated with reduced muscle mass and strength [64], decreased 
physiology capacity, and more difficulties in performing the activities of daily 
living [65]. The levels of CRP are negatively associated with appendicular lean 
body mass [66]. In addition, the increased levels of lipid peroxidation result in the 
breakdown of biological phospholipids in sarcolemma and mitochondrial mem-
brane, thus preventing the mitochondria to break down and converting fatty acid 
molecules (β-oxidation) to acyl-CoA chains in order to produce energy. Damage 
to mitochondria also increases the formation of reactive oxygen species such as 
superoxide anion [O2·−], hydroxyl radical [OH−]), and hydrogen peroxide [H2O2], 
complemented by the increased production and secretion of proinflammatory 
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cytokines such as tissue necrosis factor (TNF)-α and IL-1, 6, and 8 that trigger a 
cytokine cascade of the inflammatory cytokines that worsen the insulin resistance 
in skeletal muscle, resulting in the decrease of aerobic capacity [67].
3.2 Hormones and sarcopenia
A variety of other hormones appear to play roles in the age-related altera-
tions in muscle mass, strength function, and in the regulation of muscle 
metabolism [68].
Testosterone appears to be the central hormone involved in the development of 
sarcopenia. Testosterone is an important physiologic steroid hormone in muscle 
mass maintenance. Endogenous testosterone which naturally produced within the 
endocrine system in both men and women decline gradually with age, correlating 
with decreased muscle strength it increases both muscle mass and activates adult 
stem cells (i.e., satellite cells) leading to improved muscle function [69].
Normal growth hormone (GH) level is associated with notable protection from 
age-related disease in general, and more specifically against sarcopenia. The levels 
of GH and GH binding proteins declines upon aging. Growth hormone deficiency 
leads to the loss of muscle mass but not muscle strength [69, 70].
Skeletal muscle is the major organ in which the insulin-mediated glucose uptake 
by glucose transporter 4 (GLUT4) takes place. Lack of insulin, or IGF-1, or insulin 
resistance leads to accelerated development of sarcopenia. The muscle IGF-I level 
declines in aged population.
The primary action of insulin in skeletal muscle is to stimulate glucose uptake 
and metabolism. In physiological condition as insulin resistance, there is a gradual 
muscle wasting by several mechanisms such as the following: (a) suppression 
of PI3K/Akt signaling leading to the activation of caspase-3 and the ubiquitin-
proteasome proteolytic pathway causing muscle protein degradation; (b) beta-
adrenergic stimulation increases the lipolysis of the cell membrane, breaking 
down G-proteins that lead to interfering with growth hormone/insulin growth 
factor-1 receptor bind and diminished muscle regeneration; (c) advancement 
of gluconeogenesis metabolic pathway; (d) upregulation of sterol regulatory 
element-binding protein 1c (SREBP-1c); and (e) altering triglyceride and choles-
teryl esters transport in the core of plasma lipoproteins, which causes triglycerides 
to accumulate in skeletal muscle [71, 72]. It has been reported that IGF-I drops 
1.88 ng/ml/year in men and 2.13 ng/ml/year in women [73]. Circulating IGF-I level 
was found to be significantly reduced in sarcopenia patients [74]. mTOR signaling 
is a significant factor in sarcopenia, and mTOR signaling is altered by the change 
of IGF-I level [75].
Various medical problems and health conditions such as muscle weakness 
reduced the muscle mass that is predominantly a type II muscle fiber, bone pain, 
and systematic oxidative stress linked to 1,25-dihydroxyvitamin D [1,25(OH)2D]/
vitamin D deficiency. The vitamin D deficiency expands the sarcomeres space that 
allows the infiltration of irregular connective tissue and fat tissue. As such, the 
vitamin D deficiency resulting in reducing physical performance such as gait speed 
and cognitive performance (such as sustained attention and speed of informa-
tion processing), mental well-being (e.g., depression), falls and leading to bone 
deformities. The vitamin D deficiency is a serious medical condition that drastically 
affects the quality of life of older adults. There are a number of reasons that play 
a role in vitamin D deficiencies in older adults. Since the majority of the time they 
spend indoors, they get minimal exposure to sunlight, lacking resistance exercise 
which is well known to preserve muscle function, and their skin is less exposed to 
the synthesis of vitamin D [76, 77].
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3.3 Vitamin E
Vitamin E, which is a group of eight fat soluble compounds, four tocopherols 
(α, β, γ, and δ) and four tocotrienols (α, β, γ, and δ), is a lipid soluble vitamin, with 
potent antioxidant properties and has a role in the modulation of signaling path-
ways. The vitamin E molecules deficiency, due to malabsorption or malnutrition, 
worsens age-associated skeletal dysfunction and enhances muscle degeneration, 
thus increasing sarcopenia [78, 79].
4. Conclusions
This chapter reviewed the possible mechanisms that are linked to sarcopenia. 
The etiology of sarcopenia is multifactorial, including a wide range of both intra-
muscular and extra muscular factors. This chapter focuses only on the intramus-
cular factors that include oxidative stress, inflammation, lack of vitamins, and 
hormones. Extra muscular factors include adult stem cells, extra cellular matrix 
(e.g., the function of matrix metaloproteinases), capillary bed, and neuronal 
activity.
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